BuyCancerDrugs.com BuyCancerDrugs.com
BuyCancerDrugs.com BuyCancerDrugs.com
OncologyJournal.org - The Latest Medical News and Information for Patients Diagnosed with Cancer
Search OncologyJournal.org
Browse by Cancer Type or Cancer Drug

Go Back   OncologyJournal.org - The Latest Medical News and Information for Patients Diagnosed with Cancer > Blogs > admin
Connect with Facebook


Rate this Entry

Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand

Posted 07-29-2010 at 06:14 PM by admin
July 29, 2010 05:00 AM Eastern Daylight Time

Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand

LOS ANGELES & MELBOURNE, Australia--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

Abraxis BioScience granted exclusive marketing rights to Specialised Therapeutics for ABRAXANE in New Zealand. Specialised Therapeutics will commence distribution upon receiving reimbursement approval of ABRAXANE from the New Zealand pharmaceutical reimbursement authority, Pharmac. ABRAXANE is currently fully reimbursed for “Metastatic breast cancer after failure of prior therapy” in Australia under the Pharmaceutical Benefits Scheme.


Read the rest of the article here.

©2010 Business Wire
Total Comments 0

Comments

 

All times are GMT. The time now is 12:35 AM.


Powered by vBulletin® Version 3.8.1
Copyright ©2000 - 2010, Jelsoft Enterprises Ltd.